BR112022003892A2 - Composições imunogênicas contra doenças entéricas e métodos para a preparação das mesmas - Google Patents
Composições imunogênicas contra doenças entéricas e métodos para a preparação das mesmasInfo
- Publication number
- BR112022003892A2 BR112022003892A2 BR112022003892A BR112022003892A BR112022003892A2 BR 112022003892 A2 BR112022003892 A2 BR 112022003892A2 BR 112022003892 A BR112022003892 A BR 112022003892A BR 112022003892 A BR112022003892 A BR 112022003892A BR 112022003892 A2 BR112022003892 A2 BR 112022003892A2
- Authority
- BR
- Brazil
- Prior art keywords
- typhi
- polysaccharide
- methods
- salmonella
- immunogenic compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201921035435 | 2019-09-03 | ||
| PCT/IN2020/050763 WO2021044436A2 (en) | 2019-09-03 | 2020-09-02 | Immunogenic compositions against enteric diseases and methods for its preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022003892A2 true BR112022003892A2 (pt) | 2022-05-24 |
Family
ID=72659843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022003892A BR112022003892A2 (pt) | 2019-09-03 | 2020-09-02 | Composições imunogênicas contra doenças entéricas e métodos para a preparação das mesmas |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20230149524A1 (https=) |
| EP (2) | EP4249061A3 (https=) |
| JP (2) | JP7732974B2 (https=) |
| KR (2) | KR20240155975A (https=) |
| CN (1) | CN114728053A (https=) |
| AR (1) | AR119884A1 (https=) |
| AU (1) | AU2020343943A1 (https=) |
| BR (1) | BR112022003892A2 (https=) |
| CA (1) | CA3149972A1 (https=) |
| CO (1) | CO2022003789A2 (https=) |
| CR (1) | CR20220132A (https=) |
| EC (1) | ECSP22031077A (https=) |
| GB (2) | GB2603362B (https=) |
| GE (2) | GEP20257808B (https=) |
| IL (1) | IL291006B2 (https=) |
| JO (1) | JOP20200214A1 (https=) |
| MA (1) | MA56283A1 (https=) |
| MX (1) | MX2022002693A (https=) |
| PE (1) | PE20221442A1 (https=) |
| PH (1) | PH12022550525A1 (https=) |
| PY (1) | PY2051122A (https=) |
| WO (1) | WO2021044436A2 (https=) |
| ZA (1) | ZA202203368B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121569027A (zh) * | 2023-07-21 | 2026-02-24 | 葛兰素史克生物有限公司 | 免疫原性组合物 |
| WO2025217253A1 (en) * | 2024-04-12 | 2025-10-16 | Neogen Corporation | Neutralizing compositions and related methods |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4057685A (en) | 1972-02-02 | 1977-11-08 | Abbott Laboratories | Chemically modified endotoxin immunizing agent |
| US4673574A (en) | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
| US4459286A (en) | 1983-01-31 | 1984-07-10 | Merck & Co., Inc. | Coupled H. influenzae type B vaccine |
| AU1420897A (en) * | 1996-12-18 | 1998-07-15 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Conjugate vaccine for (salmonella paratyphi) a |
| DE69941574D1 (de) | 1998-08-19 | 2009-12-03 | Baxter Healthcare Sa | Immunogenes beta-propionamido-gebundenes polysaccharid-protein konjugat geeignet als impfstoff und hergestellt bei verwendung von n-acryloyliertem polysaccharid |
| US20070184072A1 (en) | 2005-04-08 | 2007-08-09 | Wyeth | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| PE20110072A1 (es) | 2005-06-27 | 2011-02-04 | Glaxosmithkline Biolog Sa | Composicion inmunogenica |
| AU2007294731B2 (en) | 2006-09-13 | 2014-04-17 | Abbvie Inc. | Cell culture improvements |
| GB0700135D0 (en) * | 2007-01-04 | 2007-02-14 | Glaxosmithkline Biolog Sa | Vaccine |
| FR2938265B1 (fr) | 2008-11-12 | 2011-07-15 | Univ Claude Bernard Lyon | Procede pour le pilotage d'un traitement de depolymerisation par ultrasons d'un biopolymere hydrosoluble |
| CA2836153C (en) * | 2009-12-17 | 2016-06-21 | Fina Biosolutions, Llc | Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines |
| US9011871B2 (en) * | 2011-11-07 | 2015-04-21 | University Of Maryland, Baltimore | Broad spectrum vaccine against typhoidal and non-typhoidal Salmonella disease |
| IN2012MU00206A (https=) * | 2012-01-20 | 2013-08-09 | ||
| MX354103B (es) | 2012-01-30 | 2018-02-13 | Serum Inst India Ltd | Composicion inmunogenica. |
| CN102935226B (zh) * | 2012-11-16 | 2014-01-22 | 罗益（无锡）生物制药有限公司 | 伤寒甲型副伤寒结合疫苗及其制备方法 |
| KR102447303B1 (ko) * | 2013-08-24 | 2022-09-23 | 브하라트 바이오테크 인터내셔날 리미티드 | 박테리아성 백신 및 그의 제조방법 |
| CN104383532A (zh) * | 2014-12-02 | 2015-03-04 | 云南沃森生物技术股份有限公司 | 一种用乙肝表面抗原为载体蛋白的细菌多糖蛋白结合物疫苗及其制备方法 |
| CN104587461A (zh) * | 2015-01-05 | 2015-05-06 | 云南沃森生物技术股份有限公司 | 伤寒、甲型乙型副伤寒多糖蛋白结合型多价联合疫苗 |
| WO2017006349A1 (en) * | 2015-07-04 | 2017-01-12 | Bharat Biotech International Limited | Polysaccharide vaccine formulations and processes for industrial production of bacterial polysaccharides |
| US20190134177A1 (en) * | 2016-04-25 | 2019-05-09 | National Institute Of Immunology | Conjugate for vaccination against typhoid comprising chemical conjugate of vi polysaccharide and flagellin, a process for producing the same and a composition comprising the conjugate |
| MY191163A (en) | 2016-08-26 | 2022-06-03 | The Centers For Disease Control And Prevention Cdc | Multivalent vaccine composition |
| US11739356B2 (en) * | 2017-05-05 | 2023-08-29 | Serum Institute Of India Private Limited | Method for removal of impurities from bacterial capsular polysaccharide based preparations |
| CN111032078A (zh) | 2017-07-18 | 2020-04-17 | 血清研究所印度私人有限公司 | 具有改善的稳定性、增强的免疫原性和降低的反应原性的免疫原性组合物及其制备方法 |
| EA202190778A1 (ru) | 2018-10-12 | 2021-08-05 | Серум Инститьют Оф Индия Прайват Лтд | Композиция комбинированной вакцины, содержащая уменьшенную дозу инактивированного полиовируса, и способ её получения |
| MX2021005500A (es) * | 2018-11-10 | 2021-09-08 | Bharat Biotech Int Ltd | Composiciones inmunogenicas de glicoconjugados multivalentes. |
-
2019
- 2019-09-03 JO JOP/2020/0214A patent/JOP20200214A1/ar unknown
-
2020
- 2020-09-02 GB GB2204276.6A patent/GB2603362B/en active Active
- 2020-09-02 BR BR112022003892A patent/BR112022003892A2/pt unknown
- 2020-09-02 WO PCT/IN2020/050763 patent/WO2021044436A2/en not_active Ceased
- 2020-09-02 IL IL291006A patent/IL291006B2/en unknown
- 2020-09-02 EP EP23184552.0A patent/EP4249061A3/en active Pending
- 2020-09-02 JP JP2022514468A patent/JP7732974B2/ja active Active
- 2020-09-02 PE PE2022000363A patent/PE20221442A1/es unknown
- 2020-09-02 AU AU2020343943A patent/AU2020343943A1/en active Pending
- 2020-09-02 MX MX2022002693A patent/MX2022002693A/es unknown
- 2020-09-02 GE GEAP202015919A patent/GEP20257808B/en unknown
- 2020-09-02 CA CA3149972A patent/CA3149972A1/en active Pending
- 2020-09-02 GE GEAP202515919A patent/GEAP202515919A/en unknown
- 2020-09-02 PH PH1/2022/550525A patent/PH12022550525A1/en unknown
- 2020-09-02 MA MA56283A patent/MA56283A1/fr unknown
- 2020-09-02 GB GB2412329.1A patent/GB2629746B/en active Active
- 2020-09-02 KR KR1020247034650A patent/KR20240155975A/ko active Pending
- 2020-09-02 CN CN202080074655.7A patent/CN114728053A/zh active Pending
- 2020-09-02 US US17/753,248 patent/US20230149524A1/en active Pending
- 2020-09-02 CR CR20220132A patent/CR20220132A/es unknown
- 2020-09-02 KR KR1020227011108A patent/KR20220087437A/ko active Pending
- 2020-09-02 EP EP20781107.6A patent/EP4025246A2/en active Pending
- 2020-09-03 PY PY202002051122A patent/PY2051122A/es unknown
- 2020-09-03 AR ARP200102458A patent/AR119884A1/es unknown
-
2022
- 2022-03-22 ZA ZA2022/03368A patent/ZA202203368B/en unknown
- 2022-03-29 CO CONC2022/0003789A patent/CO2022003789A2/es unknown
- 2022-04-01 EC ECSENADI202231077A patent/ECSP22031077A/es unknown
-
2024
- 2024-09-18 JP JP2024160658A patent/JP2024178271A/ja active Pending
- 2024-10-21 US US18/921,691 patent/US20250134980A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202091382A1 (ru) | Композиции, содержащие конъюгаты полисахарид streptococcus pneumoniae с белком, и способы их применения | |
| JOP20210148A1 (ar) | تركيبات تشتمل على متقارنات بولي سكاريد-بروتين للمكورات العقدية الرئوية وطرق استخدامها | |
| BR112014018815A8 (pt) | Composição imunogênica compreendendo conjugado proteína-polissacarídeo x de n. meningitidis | |
| Mitra et al. | Multi-serotype outer membrane vesicles of Shigellae confer passive protection to the neonatal mice against shigellosis | |
| MX392525B (es) | Composiciones inmunogenicas para su uso en vacunas neumococicas | |
| BR112018000087A2 (pt) | composições imunogênicas que compreendem antígenos de sacarídeos capsulares conjugados, kits que compreendem as mesmas e usos das mesmas | |
| NO20074638L (no) | Ny sammensetning | |
| NZ755769A (en) | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | |
| BR112018007812A2 (pt) | polissacarídeo capsular, processo para preparar um polissacarídeo capsular e para fabricar uma vacina, composição imunogênica, vacina, métodos para tratamento ou prevenção de uma infecção, para imunizar um hospedeiro humano e para induzir uma resposta imune, e, uso de uma composição imunogênica. | |
| BR112022003892A2 (pt) | Composições imunogênicas contra doenças entéricas e métodos para a preparação das mesmas | |
| BR112015005056A2 (pt) | vacinas de combinação com sorogrupo b meningococcus e d/t/p | |
| Bessler et al. | The bacterial extract OM-85 BV protects mice against influenza and Salmonella infection | |
| WO2010083477A3 (en) | Broad spectrum vaccine against non-typhoidal salmonella | |
| MX2023005221A (es) | Composiciones inmunogenicas para uso en vacunas neumococicas. | |
| BR112021024189A2 (pt) | Método para sintetizar um polissacarídeo de ramnose, produto, polissacarídeos estreptocócico sintético e de ramnose estreptocócico sintético, glicoconjugados estreptocócico e de ramnose estreptocócico, composição ou vacina imunogênica, célula hospedeira bacteriana, e, kit de partes | |
| BR112022023261A2 (pt) | Imunização bacteriana usando vacina de nanopartícula | |
| Rivera-Patron et al. | Quillaja brasiliensis leaf saponins and their nanoparticles are strong inducers of early immune responses | |
| MX2015017677A (es) | Vacuna multivalente que contiene porinas de s. typhi y s. typhimurium contra fiebre tifoidea, paratifoidea y salmonelosis no tifoideas. | |
| ZA202402956B (en) | Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof | |
| EA202191647A1 (ru) | Композиции, содержащие конъюгаты полисахарида из streptococcus pneumoniae и белка, и способы их применения | |
| SHEEP | Edinburgh EH17 7JH, Scotland |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122024027321-7 PROTOCOLO 870240110391 EM 26/12/2024 17:57. |